BMS, Dragonfly Working on Immune System-targeting Therapies for MS
Dragonfly Therapeutics and Bristol Myers Squibb (BMS) announced an expanded partnership focused on discovering and developing treatment candidates for multiple sclerosis (MS) and neuroinflammation targets. The companies have been working together in therapy research and development for cancer and autoimmune diseases using Dragonfly’s proprietary immunotherapy targeting platform.